Carl read the papersWhat it actually is
Dulaglutide is a GLP-1 receptor agonist, sold as Trulicity. Like semaglutide, it copies the gut hormone that releases insulin after a meal, lowers glucagon and slows the stomach. It is approved for type 2 diabetes in adults and children from 10, and for cutting the risk of heart attack, stroke and cardiovascular death in adults with type 2 diabetes who have heart disease or several heart risk factors.
Structurally it is an odd one. It is not a short peptide but a fusion protein of about 63 kDa: two GLP-1 look-alike chains joined to the tail (Fc) of a human antibody, made in Chinese hamster ovary cells. The finished drug has a half-life of about 5 days, so one shot covers a week.
How it’s thought to work
- GLP-1 receptor activation — Raises cAMP in pancreatic beta cells, which releases insulin when glucose is high.
- Less glucagon — Lowers glucagon, the hormone that tells the liver to push sugar into the blood.
- Slower stomach — Slows gastric emptying. Helps you feel full, and is behind most of the nausea.
- Long half-life — About 5 days, long enough for one shot a week. Steady blood levels take 2 to 4 weeks to build.
What the research says
Real, large human trials. REWIND put 9,901 people with type 2 diabetes on 1.5 mg weekly or placebo for a median 5.4 years: major cardiovascular events (heart attack, stroke, cardiovascular death) were 12% lower (HR 0.88). AWARD-11 (n=1,842) pushed the dose higher: at 36 weeks, 4.5 mg took off 4.6 kg against 3.0 kg on 1.5 mg. Head to head in SUSTAIN 7, semaglutide 1 mg took off 6.5 kg against 3.0 kg on dulaglutide 1.5 mg. So: a proper diabetes and heart drug, a modest weight drug.
- REWIND (n=9,901, median 5.4 years): 12% fewer major cardiovascular events than placebo (HR 0.88).
- AWARD-11 (n=1,842): 4.5 mg beat 1.5 mg on HbA1c (-1.77 vs -1.54 points) and weight (-4.6 vs -3.0 kg) at 36 weeks.
- SUSTAIN 7: semaglutide 1 mg beat dulaglutide 1.5 mg on weight, 6.5 kg vs 3.0 kg at 40 weeks.
- Gut side effects are the cost: 47.4% reported one in REWIND vs 34.1% on placebo; nausea rose from 13.4% (1.5 mg) to 16.4% (4.5 mg) in AWARD-11.
Reported protocols
These are the doses the peptide community actually reports running (Reddit & forums), alongside published research — logged for education, not as a recommendation to use.
| Parameter | Commonly reported range |
|---|---|
| Label dose | 0.75 mg once weekly; after 4 weeks may go to 1.5 mg; if more control is needed, up in 1.5 mg steps (3 mg, then 4.5 mg), at least 4 weeks per step |
| Maximum | 4.5 mg weekly in adults; 1.5 mg weekly in children 10 and over |
| Frequency | Once weekly, any time of day, with or without food |
| Missed dose | Take it if the next dose is at least 3 days away; if not, skip it and stay on schedule |
| Route | Subcutaneous: abdomen, thigh or upper arm, rotating sites each week |
| Community dose | Not established. Public posts we found are mostly prescription users on the label ladder; the one off-label microdosing story is a single anecdote, not a protocol |
| Prescription | A prescription medicine. These are the label doses a doctor works from, not a DIY plan |
Common use cases
| Goal | Community protocol notes |
|---|---|
| Type 2 diabetes | the approved use; 0.75 mg weekly, up to 4.5 mg if needed |
| Type 2 diabetes with heart risk | approved to lower the risk of heart attack, stroke and cardiovascular death (REWIND) |
| Weight loss on its own | not an approved use; expect a few kilos, less than semaglutide in a head-to-head trial |
Mixing it (reconstitution)
Freeze-dried peptides must be reconstituted with bacteriostatic water before they can be measured. Carl’s calculator turns “mg in the vial + ml of water + target dose” into “units on the syringe” — and tells you how long the vial lasts.
→ Open the Reconstitution Calculator
Injection & handling
It comes as a single-dose pen of 0.5 mL that should look clear and colourless. Inject under the skin of the abdomen, thigh or upper arm once a week and rotate the site each time. Time of day and food do not matter. The 4-week steps on the ladder are there for your stomach, because nausea and vomiting climb with dose. There is nothing to mix or reconstitute: the registered product is a ready-to-use pen, and SAHPRA says powder forms of GLP-1 drugs are not registered.
Stacks it appears in
- With metformin — The standard diabetes pairing. AWARD-11 tested every dose on top of metformin.
- With another GLP-1 — Semaglutide, liraglutide and tirzepatide all hit the GLP-1 receptor, so adding one doubles up on a mechanism instead of adding a new one. Switching is the usual move.
- With an amylin analogue — Cagrilintide works on a separate appetite system. The tested pairing is with semaglutide (CagriSema); we found no trial of cagrilintide with dulaglutide.
Sources
- FDA label: Trulicity (DailyMed, Jun 2026 version)
- Drugs@FDA: BLA 125469 (Trulicity)
- Gerstein et al., REWIND, Lancet 2019 (PMID 31189511)
- Frias et al., AWARD-11, Diabetes Care 2021 (PMID 33397768)
- Pratley et al., SUSTAIN 7, Lancet Diabetes Endocrinol 2018 (PMID 29397376)
- ClinicalTrials.gov NCT01394952 (REWIND)
- FDA label: Byetta (exenatide), for exenatide molecular weight
- SAHPRA PI repository: Trulicity professional information (8 Sep 2025)
- SAHPRA: Peptide Products, Public Information (May 2026)
- WADA 2026 Prohibited List
